Flotufolastat F 18 PET scanning for men with very low PSA after prostatectomy
A Prospective Study of Flotufolastat F 18 Positron Emission Tomography in Men With Very Low Prostate Specific Antigen Recurrence
This study will test whether a single flotufolastat F 18 PET scan can find sites of recurrent prostate cancer in men with very low PSA levels after radical prostatectomy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | Massachusetts General Hospital Academic / other |
| Locations | 2 sites (Boston, Massachusetts and 1 other locations) |
| Trial ID | NCT06862856 on ClinicalTrials.gov |
What this trial studies
This is a prospective, single-arm imaging study that collects flotufolastat F 18 PET/CT images to determine the detection rate of PSMA-targeted PET in men with very low PSA recurrence after radical prostatectomy. Eligible participants are adult men with histologically confirmed prostate adenocarcinoma, a non-zero PSA ≤0.20 ng/mL within 60 days of imaging, and who have been off ADT for at least 16 weeks if previously treated. The radiopharmaceutical flotufolastat F 18 is FDA-approved and will be administered as a single clinical PET/CT scan prescribed as part of standard care. About 50 participants are expected, and participation is limited to the time needed for the imaging visit.
Who should consider this trial
Good fit: Men aged 18 or older with prior localized prostate adenocarcinoma treated by radical prostatectomy and a detectable PSA ≤0.20 ng/mL obtained within 60 days (and off ADT ≥16 weeks if applicable) who have a clinical flotufolastat F 18 PET/CT ordered.
Not a fit: Patients with PSA levels above 0.20 ng/mL, who have not had a prostatectomy, who cannot undergo PET/CT, or who have recent ADT or other conditions that confound imaging are less likely to benefit from this specific enrollment.
Why it matters
Potential benefit: If successful, the scan could help find recurrent disease earlier and more accurately at very low PSA levels, which may guide targeted salvage treatments.
How similar studies have performed: Other PSMA-targeted PET tracers have demonstrated improved detection of recurrent prostate cancer at low PSA levels, and flotufolastat F 18 is an FDA-approved PSMA radiotracer, so this work builds on established imaging evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants must have a history of localized histologically confirmed adenocarcinoma of the prostate and have received radical prostatectomy (RP) with curative intent. * Participants must have measurable disease, defined as a non-zero PSA value post-RP that is concerning for biochemically recurrent or persistent disease, is ≤0.20 ng/mL, and obtained within 60 days of PET/CT. * At least 6 weeks must have elapsed after RP. If previously taking ADT, it should have been discontinued at least 16 weeks prior to PET. * Participants with a clinical flotufolastat F 18 PSMA PET/CT scan prescribed as part of the standard of care management. * Age ≥18 years. * Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Participants currently receiving ADT (defined as surgical orchidectomy; luteinizing hormone-releasing hormone \[LHRH\] agonist alone \[continuous or intermittent\]; LHRH antagonist alone \[continuous or intermittent\]; administration or use of a first or second generation anti-androgen alone or in combination with an LHRH agonist/antagonist). * Participants who are receiving any other investigational agents for this condition within five biological half-lives prior to administration of flotufolastat F 18. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to flotufolastat F 18 or other agents used in study. * Participants receiving any of the following substances will be considered ineligible: x-ray contrast agent \<24 hours prior to the flotufolastat F 18 PET and any other PET imaging agent within 24 hours or 10 half-lives, whichever is longer, prior to the flotufolastat F 18 PET/CT. As part of the enrollment/informed consent procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product.
Where this trial is running
Boston, Massachusetts and 1 other locations
- Massachusetts General Hospital — Boston, Massachusetts, United States (Recruiting)
- Dana Farber Cancer Institute — Boston, Massachusetts, United States (Recruiting)
Study contacts
- Principal investigator: Jason Efstathiou, MD, DPhil — Massachusetts General Hospital
- Study coordinator: Jason Efstathiou, MD, DPhil
- Email: jefstathiou@mgb.org
- Phone: 617-726-5866
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.